<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672642</url>
  </required_header>
  <id_info>
    <org_study_id>SPY PCC 2020</org_study_id>
    <nct_id>NCT04672642</nct_id>
  </id_info>
  <brief_title>Evaluation of the SpyGlass DS for Detection of Residual Pancreatic Calculations</brief_title>
  <official_title>Evaluation of the SpyGlass DS vs Standard Method for Detection of Residual Pancreatic Calculations After Endoscopic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital St. Joseph, Marseille, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital St. Joseph, Marseille, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy of the SpyGlass DS for the detection of&#xD;
      residual pancreatic calculations after endoscopic treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Residual pancreatic stones detected by the Spyglass DS</measure>
    <time_frame>baseline</time_frame>
    <description>rate of residual pancreatic stones detected by the SpyGlass DS, after a treatment by CT-scan and ERCP (recommended standard method) showing no stones in the Wirsung's duct. .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual pancreatic stones extracted by the SpyGlass DS accessory (the SpyGlass Basket)</measure>
    <time_frame>baseline</time_frame>
    <description>rate of residual pancreatic stones extracted by by the SpyGlass DS accessory (the SpyGlass Basket) after being detected by the SpyGlass DS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score for pancreatic pain</measure>
    <time_frame>preoperative, 1 month, 6 months and 12 months</time_frame>
    <description>pain visual analogue scale from 0 (no pain) to 10 (worst pain possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic consumption</measure>
    <time_frame>preoperative, 1 month, 6 months and 12 months</time_frame>
    <description>level of analgesic (if several analgesics of different levels are used, the analgesic of the highest level will be taken into account each time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic consumption</measure>
    <time_frame>preoperative, 1 month, 6 months and 12 months</time_frame>
    <description>total daily dose (mg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients hospitalized for pancreatic pain</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of operated patients requiring partial / total pancreatectomy, or pancreas-jejunal shunts for pancreatic pain</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients requiring endoscopic treatment (placement of pancreatic-duct stent, extraction of pancreatic stones)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-administered quality of life questionnaire score</measure>
    <time_frame>preoperative, 1 month, 6 months and 12 months</time_frame>
    <description>36-Item Short Form Health Survey (SF-36). SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE rate and type</measure>
    <time_frame>during and immediately after the operation, 7 days, 1 month, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Pancreatitis, Chronic</condition>
  <arm_group>
    <arm_group_label>SpyGlass DS after endoscopic treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SpyGlass DS</intervention_name>
    <description>Detection by the SpyGlass DS of residual pancreatic stones not detected by the standard method (CT scan and ERCP)</description>
    <arm_group_label>SpyGlass DS after endoscopic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged 18 and over;&#xD;
&#xD;
          -  with chronic calcifying pancreatitis;&#xD;
&#xD;
          -  having already received endoscopic treatment for pancreatic pain related to stenosis&#xD;
             and / or pancreatic stones;&#xD;
&#xD;
          -  having given free, informed and written consent;&#xD;
&#xD;
          -  being affiliated to a social security scheme or beneficiary of such a scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindications to performing an upper digestive endoscopy;&#xD;
&#xD;
          -  haemorrhagic disease, haemostasis and coagulation disorder (PR &lt;60%, PTT&gt; 40 s and&#xD;
             platelets &lt;60,000 / mm3;&#xD;
&#xD;
          -  pregnant or breastfeeding woman;&#xD;
&#xD;
          -  adult patient protected (guardianship or curatorship), or deprived of liberty by a&#xD;
             judicial or administrative decision;&#xD;
&#xD;
          -  person subject to a safeguard measure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cécile Bielmann</last_name>
    <phone>0033488731070</phone>
    <email>cbielmann@hopital-saint-joseph.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rahamia Ahamada</last_name>
    <phone>0033488731071</phone>
    <email>rahamada@hopital-saint-joseph.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Saint Jospeh Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile Bielmann</last_name>
      <email>cbielmann@hopital-saint-joseph.fr</email>
    </contact>
    <investigator>
      <last_name>Arthur LAQUIERE, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

